Introduction {#s1}
============

Calcium/calmodulin-dependent protein kinase II (CAMK2) is a calcium-activated serine/threonine kinase that is extremely abundant in the brain, comprising as much as 0.3% of the total brain protein content ([@bib2]). CAMK2 is highly enriched at the synapses and is necessary for the process of long-term potentiation (LTP), the activity-dependent strengthening and modulation of synaptic activity that is thought to be the molecular basis of some forms of learning and memory ([@bib12]; [@bib15]). In humans, there are four genes encoding distinct CAMK2 iso-enzymes. CAMK2A and CAMK2B are the predominant isoforms in the nervous system, with CAMK2A being expressed 3--4 times higher than CAMK2B ([@bib8]). Each enzyme comprises a kinase domain, a regulatory domain and an association domain. Structurally CAMK2 holoenzymes are homo- or hetero-oligomers, consisting of 12 or 14 CAMK2 subunits ([@bib11]). The holoenzyme assembly requires the carboxy-terminal association domain, which forms stacked pairs of hexameric or heptameric rings with the regulatory and kinase domain projecting radially to interact with other essential proteins for CAMK2 function and localization ([@bib3]). In the absence of calcium signalling, CAMK2 is inactive, as the regulatory domain inhibits kinase function ([@bib41]). This auto-inhibition is relieved when calcium-loaded calmodulin binds to the regulatory domain, thereby exposing the kinase domain and allowing it to phosphorylate target substrates ([@bib20]). Ca^2+^-Calmodulin binding also exposes Thr286 on the regulatory domain of CAMK2A, which becomes phosphorylated in trans by adjacent subunits. Once this residue is phosphorylated, the enzyme is persistently active, even in the absence of continual Ca^2+^-Calmodulin signaling ([@bib26]; [@bib35]). This switch from auto-inhibition to autonomous, persistent activity is thought to constitute a biochemical form of memory, which marks the neuron for having experienced a previous calcium influx ([@bib3]; [@bib34]; [@bib35]).

Mice that are homozygous null for *CAMK2A* are viable and display impaired spatial memory and reduced LTP in the hippocampus ([@bib30], [@bib31]). The heterozygous mutant (*Camk2a^+/-^*) show a significant deficit in spatial working memory and contextual fear memory ([@bib6]; [@bib19]). More recently, it was demonstrated that mice with neuron-specific conditional knock-out of *CAMK2A* similarly displayed learning deficits and defects in LTP that were comparable to the complete knockout mice ([@bib1]). These findings suggest that neuron-intrinsic CAMK2A function is indispensable during the period of learning for memory formation. CAMK2 is conserved in invertebrates, such as *D. melanogaster* and *C. elegans*, where the kinase also plays critical roles in behavioral and cognitive traits ([@bib5]; [@bib10]; [@bib25]; [@bib28]). In *C. elegans*, the only CAMK2 is encoded by the *unc-43* gene, which is essential for synaptic function ([@bib28]). Loss of *unc-43* causes worms to have flaccid muscle tone, locomotion defects and spontaneous body contractions that resemble seizures ([@bib25]).

In pediatric care, global developmental delay in infants is defined as a significant functional delay in two or more developmental domains including gross and fine motor function, speech and language, cognition, social development and personal skills ([@bib24]). These defects are detected at an early age in children age five years or under, and can persist throughout life ([@bib29]). About 25--50% of identified case are caused by germline genetic changes, including chromosomal abnormalities, copy number variants and monogenic mutations ([@bib32]; [@bib38]). For many patients with global neuro-developmental delay, the genetic etiology remains unknown.

Results {#s2}
=======

Here, we report the identification of a consanguineous family from Jordan with two affected children manifesting global neuro-developmental delay with frequent seizures and convulsions. The two affected siblings had no dysmorphic features but failed to develop the ability to walk or speak ([Figure 1A,B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). They displayed progressive psychomotor retardation with hypotonic muscles (Supplemental Material, [Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}). Electroencephalogram (EEG) analysis revealed abnormal epileptiform transients ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), consistent with frequent myoclonic seizures. Magnetic resonance imaging (MRI) scan showed no major structural defects in the brain of proband II:4 ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Serum metabolite levels were normal, ruling out potential lysosomal storage disorders.

![A new syndrome of global neuro-developmental delay with seizures caused by a biallelic mutation in *CAMK2A*.\
(**A**) Pedigree of a consanguineous Jordanian family with two affected siblings with germline homozygous mutations in *CAMK2A*. The genotypes of all individuals were verified by Sanger sequencing. (**B**) Photographs of the two affected siblings with normal head circumferences. (**C**) EEG graph of patient II.I showing abnormal epileptiform transients (red boxes) (**D**) Homozygosity mapping delineates one candidate locus on chromosome 5. (**E**) *CAMK2A* exonic structure and CAMK2A protein domains. Patients II:1 and II:4 carry biallelic missense mutation p. H477Y located in CAMK2A association domain (AD). Nucleotide change c.1429 C \> T refers to position on *CAMK2A* cDNA.](elife-32451-fig1){#fig1}

###### Video of patient II.1
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###### Video of patient II.4
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Assuming autosomal recessive inheritance, we performed identity-by-descent (IBD) homozygosity mapping using genomic DNA from both parents, two affected probands and three healthy siblings. Only one candidate locus greater than 5 cM on chromosome 5 spanning 28 Mb was delineated ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Whole-exome sequencing was subsequently performed on index case II:1. After filtering for variants with low quality and low sequencing coverage, 72 homozygous variants were identified, out of which four lie within the Chr. 5 IBD region ([Table 1](#table1){ref-type="table"}). Three of the homozygous variants had been previously annotated as known polymorphisms with minor allele frequencies \> 0.0001. In addition, healthy individuals who are homozygous for the minor alleles had been identified in genomic sequencing databases such as dbSNP and gnomAD ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). We therefore filtered out these variants as non-pathogenic. The fourth homozygous variant within the IBD region mapped to the *CAMK2A* gene (MIM: 114078), resulting in a missense mutation p.His477Tyr that has never been observed in previous large-scale sequencing databases and our in-house ethnically-matched cohort ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Using Sanger sequencing, this private mutation was confirmed to segregate with the disease in all seven family members ([Figure 1A,D](#fig1){ref-type="fig"}).
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###### List of homozygous variants identified by Whole Exome Sequencing.

  -------------------------------------------------------------------------------------------------------------------
  Chr     Position          Gene                 cDNA variant                                 Protein variant
  ------- ----------------- -------------------- -------------------------------------------- -----------------------
  1       33,476,435        *AK2*                c.\*45--1G \> T                              

  1       36,752,343        *THRAP3*             c.512C \> T                                  p.Ser171Phe

  1       36,932,102        *CSF3R*              c.2273C \> T                                 p.Thr758Ile

  1       39,758,439        *MACF1*              c.1931G \> T                                 p.Gly644Val

  1       145,365,316       *NBPF10*             c.9941G \> A                                 p.Gly3314Glu

  2       11,758,842        *GREB1*              c.3841G \> A                                 p.Ala1281Thr

  2       29,404,617        *CLIP4*              c.1976G \> A                                 p.Arg659Gln

  2       64,779,195        *AFTPH*              c.587G \> A                                  p.Gly196Glu

  2       238,277,211       *COL6A3*             c.4895G \> A                                 p.Arg1632Gln

  2       241,987,827       *SNED1*              c.1369G \> A                                 p.Glu457Lys

  3       38,348,802        *SLC22A14*           c.574G \> A                                  p.Ala192Thr

  3       44,672,687        *ZNF197*             c.524C \> T                                  p.Ala175Val

  3       47,452,772        *PTPN23*             c.3484C \> T                                 p.Arg1162Trp

  3       52,556,184        *STAB1*              c.6403C \> G                                 p.Pro2135Ala

  3       67,426,232        *SUCLG2*             c.1235T \> C                                 p.Ile412Thr

  3       197,422,844       *KIAA0226*           c.1366C \> T                                 p.Arg456Trp

  4       9,174,981         *FAM90A26P*          c.83T \> G                                   p.Val28Gly

  4       9,175,603         *FAM90A26P*          c.211C \> G                                  p.Pro71Ala

  4       10,089,539        *WDR1*               c.743A \> G                                  p.His248Arg

  4       15,529,151        *CC2D2A*             c.1231T \> G                                 p.Ser411Ala

  5       74,021,852        *GFM2*               c.1820_1825delTTGAGT                         p.Glu608_Phe609del

  5       78,610,479        *JMY*                c.2464C \> A                                 p.Pro822Thr

  **5**   **149,602,589**   ***CAMK2A***         **c.1429C \> T**                             **p.His477Tyr**

  5       154,199,950       *C5orf4*             c.928G \> A                                  p.Glu310Lys

  5       156,456,715       *HAVCR1*             c.1090G \> A                                 p.Ala364Thr

  5       156,479,452       *HAVCR1*             c.590_592delCAA                              p.Thr198del

  6       26,509,392        *BTN1A1*             c.1571G \> A                                 p.Gly524Glu

  6       27,215,709        *PRSS16*             c.119G \> A                                  p.Ser40Asn

  6       32,806,007        *TAP2*               c.4C \> T                                    p.Arg2Trp

  6       33,260,924        *RGL2*               c.1876G \> A                                 p.Gly626Arg

  6       38,704,952        *DNAH8*              c.221C \> A                                  p.Ala74Asp

  6       43,412,643        *ABCC10*             c.2807C \> T                                 p.Pro936Leu

  6       129,932,746       *ARHGAP18*           c.1054C \> T                                 p.Arg352Ter

  6       131,946,054       *MED23*              c.235C \> T                                  p.Leu79Phe

  6       151,674,121       *AKAP12*             c.4595_4596insGGC                            p.Asp1532delinsGluAla

  6       168,479,677       *FRMD1*              c.98A \> C                                   p.Glu33Ala

  7       5,352,665         *TNRC18*             c.7851_7856dupCTCCTC                         p.Ser2618_Ser2619dup

  7       45,123,857        *NACAD*              c.1922T \> C                                 p.Val641Ala

  7       143,884,437       *ARHGEF35*           c.1040C \> T                                 p.Thr347Ile

  7       149,422,981       *KRBA1*              c.1304C \> T                                 p.Ala435Val

  7       151,680,130       *GALNTL5*            c.428A \> G                                  p.Tyr143Cys

  8       12,285,064        *FAM86B1\|FAM86B2*   c.310T \> C                                  p.Ser104Pro

  8       12,285,250        *FAM86B2*            c.808C \> T                                  p.Arg270Trp

  8       86,574,132        *REXO1L1*            c.1595A \> C                                 p.Asp532Ala

  9       12,775,863        *LURAP1L*            c.149_150insTGGCGG                           p.Gly49_Gly50dup

  9       40,706,047        *FAM75A3*            c.3704A \> G                                 p.His1235Arg

  9       41,323,425        *FAM75A4*            c.1908C \> T                                 p.Arg637Trp

  9       41,323,469        *FAM75A4*            c.1864G \> A                                 p.Gly622Asp

  9       43,822,668        *CNTNAP3B*           c.1222C \> T                                 p.Leu408Phe

  10      51,748,684        *AGAP6*              c.209G \> A                                  p.Arg70Gln

  10      81,471,741        *FAM22B*             c.2137T \> C                                 p.Trp713Arg

  11      1,651,198         *KRTAP5-5*           c.129_137delAGGCTGTGG                        p.Gly44_Gly46del

  11      12,316,388        *MICALCL*            c.1408_1410dupCCT                            p.Pro470dup

  12      7,045,917         *ATN1*               c.1488_1508delGCAGCAGCAGCAGCAGCAGCA          p.Gln496_Gln502del

  12      7,045,920         *ATN1*               c.1491_1508delGCAGCAGCAGCAGCAGCA             p.Gln497_Gln502del

  13      99,461,564        *DOCK9*              c.1271_1272insA                              p.Leu425LeufsTer?

  13      114,503,875       *FAM70B*             c.500_509 + 72delCCTGCGGGAGG\                
                                                 TGAGGGGCACCGGGGACCCCCATATC\                  
                                                 TACACCTGCGGGAGGTGAGGGGC\                     
                                                 GCTGGGGACCCCCGTATCTACA                       

  14      105,411,514       *AHNAK2*             c.10274C \> T                                p.Ala3425Val

  14      106,994,118       *IGHV3-48*           c.47G \> A                                   p.Gly16Asp

  16      29,496,359                             c.916T \> C                                  p.Ser306Pro

  16      30,772,988        *C16orf93*           c.82G \> A                                   p.Ala28Thr

  16      70,215,817        *CLEC18C*            c.521C \> T                                  p.Ala174Val

  17      39,211,189        *KRTAP2-2*           c.275G \> C                                  p.Cys92Ser

  19      1,026,716         *CNN2*               c.56A \> C                                   p.Lys19Thr

  19      10,084,460        *COL5A3*             c.3584T \> C                                 p.Val1195Ala

  19      14,517,213        *CD97*               c.1892G \> A                                 p.Ser631Asn

  21      36,042,462        *CLIC6*              c.776_805delGCGTAGAAGCGGGGGTCCCGGCGGGGGACA   p.Val260_Ser269del

  22      18,834,773                             c.329C \> T                                  p.Thr110Ile

  X       48,920,059        *CCDC120*            c.110A \> G                                  p.Asp37Gly

  X       55,116,478        *PAGE2*              c.25T \> A                                   p.Ser9Thr

  X       150,832,702       *PASD1*              c.954_971delCCCAATGGACCAGCAGGA               p.Pro319_Asp324del

  X       153,050,158       *SRPK3*              c.1_5delGACAG                                p.Thr2LeufsTer57

  X       154,010,046       *MPP1*               c.978A \> C                                  p.Glu326Asp
  -------------------------------------------------------------------------------------------------------------------

CAMK2A is a neuron-specific, highly abundant serine/threonine kinase that plays critical roles in synaptic plasticity. To understand how neuronal function is affected due to the mutation in CAMK2A, we reprogrammed primary dermal fibroblasts from patient II.4 into iPSCs, differentiated them into neurons and measured population-level neuronal activity using a multi-electrode array (MEA) system ([Figure 2A](#fig2){ref-type="fig"}). Compared to H1 embryonic stem cell derived neurons and an unrelated CAMK2A wild-type iPSC control, the patient's iPSCs were equally efficient in differentiating into mature neurons expressing neuronal markers TUJ1 and MAP2 after 21 days of *in vitro* differentiation ([Figure 2B](#fig2){ref-type="fig"}). When these differentiated neurons were plated on MEA plates to measure spontaneous action potentials, we observed a significant reduction in both the total number of spontaneous spikes ([Figure 2C](#fig2){ref-type="fig"}, left) and the mean firing rate ([Figure 2C](#fig2){ref-type="fig"}, right) in the patient-derived neurons harboring the p.H477Y mutation compared to the wild-type controls, suggesting that CAMK2A^H477Y^ causes a profound functional defect in cultured neurons.

![*CAMK2A* mutant iPSC-derived neurons are functionally less active.\
(**A**) Schematic of the hPSC-derived neuronal activity assay with representative image of iPSC-derived neurons plated on a multi-electrode array (**B**) Representative confocal images of immunofluorescence staining of neuronal lineage markers TUJ1 (green) and MAP2 (red) show efficient differentiation of iPSCs into neurons. Scale bar represents 20 µm. (**C**) Graphs showing the number of neuron-evoked spikes and mean firing rate detected by multi-electrode arrays. (n = 7 per line per time-point; Values shown as mean ±SEM; Two-way ANOVA with Tukey post-hoc test; \*p\<0.05 and \*\*\*p\<0.001).](elife-32451-fig2){#fig2}

The CAMK2A enzyme consists of an N-terminal catalytic kinase domain, a Ca^2+^-calmodulin-binding regulatory domain and a C-terminal association domain (AD) that is necessary for the assembly of the 12- or 14-subunit holoenzyme. The identified mutation, p.H477Y is located in the association domain ([Figure 1E](#fig1){ref-type="fig"}) and affects a histidine residue that is invariant across all vertebrate and invertebrate CAMK2A homologues. It is also conserved in other human CAMK2 paralogs with a similar association domain such as CAMK2B, CAMK2D and CAMK2G ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In addition, this mutation is predicted to be deleterious by both SIFT, PolyPhen and MCAP algorithms. Structurally, His477 is located at the dimeric interface that forms part of the extensive interaction surface at the 'equatorial' plane of the CAMK2A holoenzyme ([Figure 3B](#fig3){ref-type="fig"}). Based on prior findings that CAMK2A oligomerization through its association domain is indispensable for substrate phosphorylation and synaptic localization ([@bib3]), we hypothesize that the p.H477Y allele is hypomorphic and that biallelic loss-of-function in CAMK2A is the direct cause for the neurodevelopmental phenotypes in the two probands.

![p.H477Y affects CAMK2A oligomerization and protein stability.\
(**A**) Sequence conservation of CAMK2A homologs. Histidine 477 (H477) is highlighted in red. (**B**) X-ray crystal structure of human CAMK2A AD tetradecamer (PDB: 5IG3). H477 (red) is located at the equatorial dimer interface. (**C**) Defective oligomerization of the p.H477Y mutant. 293 T cells were transiently transfected with FLAG tagged wild-type CAMK2A and CAMK2A^H477Y^. A third mutant, CAMK2A^H477X^ which lacks part of the AD (a.a. 478--489) was used as positive control. (**D**) Defective self-association of the p.H477Y mutant. The indicated FLAG- and HA-tagged CAMK2A wild-type and mutant proteins were synthesized *in vitro* using rabbit reticulocyte lysate. FLAG-GFP was used a negative control. FLAG-tagged proteins were immunoprecipitated using anti-FLAG M2 agarose resin in the presence of 1% NP40. Co-immunoprecipitated proteins were analyzed by SDS-PAGE. \*, IgG light chain. \^, IgG heavy chain. (**E**) p.H477Y mutation lowers expression of CAMK2A in cells. 293 T cells were transfected with reporter plasmids encoding GFP-tagged wild-type CAMK2A, CAMK2A^H477Y^ and CAMK2A^H477X^ mutants, followed by T2A peptide and mCherry. Representative confocal images show lower expression of mutant GFP- CAMK2A^H477Y^ compared to wild-type. Scale bar represents 100 µm. (**F**). p.H477Y decreases CAMK2A stability via proteasomal degradation. 293 T cells were transfected as in (**E**) and treated with 10 µM MG132 or DMSO for 16 hr. 10 µg total cell lysate was used for SDS-PAGE and Western blot.](elife-32451-fig3){#fig3}

To measure the oligomerization potential of the CAMK2A^H477Y^ mutant in cells, we transiently expressed FLAG-tagged wild-type CAMK2A and CAMK2A^H477Y^ mutant in 293 T cells, which do not express endogenous CAMK2A. A third mutant CAMK2A^H477X^, which lacks amino acids 477--489 and thus encodes a truncated association domain, was used as an additional control. Using native lysis conditions that preserve non-covalent macromolecular interactions, we found that wild-type CAMK2A forms a prominent complex with an apparent molecular weight \~1 MDa ([Figure 3C](#fig3){ref-type="fig"}, Native-PAGE, lane 2), which is consistent with the 12- or 14- subunit CAMK2A holoenzyme ([@bib3]). As compared to wild-type CAMK2A, the \~1 MDa, putatively oligomeric species was drastically reduced for the p.H477Y mutant and was undetectable for the p.H477X mutant ([Figure 3C](#fig3){ref-type="fig"}, Native-PAGE, lane 3 and 4 vs. lane 2). Next, we examined the ability of *in vitro* translated CAMK2A to self-oligomerize in a cell-free system. In contrast to the negative control protein GFP, wild-type FLAG-CAMK2A efficiently co-immunoprecipitated with HA-CAMK2A ([Figure 3D](#fig3){ref-type="fig"}, Lane 10 vs 11). This self-association was preserved between CAMK2A^WT^ and CAMK2A^H477Y^ ([Figure 3D](#fig3){ref-type="fig"}, lanes 12 and 15), but was completely lost between wild-type CAMK2A and the p.H477X mutant ([Figure 3D](#fig3){ref-type="fig"}, lane 13). In contrast, we could not detect any self-association between FLAG- CAMK2A^H477Y^ and HA- CAMK2A^H477Y^ ([Figure 3D](#fig3){ref-type="fig"}, Lane 16). Taken together, these results suggest that the missense p.H477Y partially disrupts the self-association between identical CAMK2A molecules, which had been shown to be required for holoenzyme assembly. The partial loss of function of the p.H477Y mutant, as compared to a more severe mutation p.H477X, is consistent with the observed autosomal recessive inheritance of the disease in the family, where the heterozygous carriers do not display apparent neuro-developmental symptoms.

During the course of this analysis, we noticed that both p.H477Y and p.H477X mutants had reduced protein abundance. This effect on the p.H477Y mutant was, however, subtle and could not readily explain the difference in the CAMK2A oligomer observed in the native gel ([Figure 3C](#fig3){ref-type="fig"}, SDS-PAGE). As it is known that in general fully assembled oligomeric complexes have enhanced stability *in vivo* compared to partially assembled complexes with disrupted folding like CAMK2A^H477Y^ ([@bib17]; [@bib22]), we hypothesized that the p.H477Y mutant may exhibit reduced stability and undergo proteasomal degradation. To test this, 293T cells were transfected with reporter constructs that encode GFP tagged wild-type and mutant CAMK2A followed by a self-cleaving peptide T2A and mCherry ([Figure 3E](#fig3){ref-type="fig"}). The intensity of GFP fluorescence was used as a direct quantitative measure of CAMK2A stability with the mCherry as an internal control for transfection and translational efficiency. We observed a significant reduction in GFP intensity in cells expressing CAMK2A^H477Y^ and CAMK2A^H477X^ as compared to wild-type CAMK2A or GFP alone ([Figure 3E](#fig3){ref-type="fig"}) despite comparable mCherry fluorescence levels. This reduction was rescued when we treated the cells with MG132, which blocked proteasomal degradation. MG132 treamentled to enhanced accumulation of the p.H477Y and p.H477X mutant, with a greater effect on p.H477X ([Figure 3F](#fig3){ref-type="fig"}, lane 3, 4 vs lane 7, 8, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). By contrast, the level of the wild-type protein was reduced, likely due to the toxic effects of MG132 ([Figure 3F](#fig3){ref-type="fig"}, lane 2 vs. lane 6). These results suggest that in addition to causing reduced holoenzyme assembly, the p.H477Y mutation might also directly or indirectly reduce the overall CAMK2A levels by compromising its half-life.

To unequivocally demonstrate the pathogenicity of the p.H477Y allele *in vivo*, we performed rescue experiments using *C. elegans*. A single ortholog of CAMK2, encoded by *unc-43*, is present in the worm genome and its functions in the nervous system are welldocumented ([@bib25]). To study the neuronal defects caused by loss of *unc-43*, we focused on motor neuron, DA9, which has its cell body located in the pre-anal ganglion with a dendrite that extends anteriorly and a posteriorly oriented axon extending via a commissure into the dorsal nerve cord, where it proceeds anteriorly to form approximately 25 *en passant* synapses onto body wall muscles and reciprocal inhibitory neurons ([Figure 4A](#fig4){ref-type="fig"}) ([@bib13]; [@bib18]). Using mCherry-tagged UNC-43, we observed that UNC-43 could be found along the entire DA9 neuron but concentrated at synaptic boutons ([Figure 4B](#fig4){ref-type="fig"}). The homologous patient-specific mutation p.H466Y in UNC-43 (homologous to p.H477Y in human CAMK2A) significantly disrupted the synaptic localization of UNC-43 and caused the protein to be dispersed throughout the entire axon ([Figure 4B](#fig4){ref-type="fig"}). To test the consequence of UNC-43 mutation on DA9 synaptic function, we used the *itr-1 pB* promoter to express the fluorescently conjugated synaptic vesicle marker RAB-3 (RAB3::GFP) within DA9 in both the wild-type and *unc-43* mutant background. In wild-type animals, RAB-3::GFP accumulated in discrete puncta along the axon of DA9 at stereotyped synaptic locations. In the canonical *unc-43(e408)* loss-of-function mutant, we observed a reduction in individual pre-synaptic puncta fluorescence intensity as compared to wild-type animals. This phenotype could be rescued by cell-autonomous expression of wild-type *unc-43* in DA9. However, expression of *unc-43* harboring the homologous patient mutation UNC-43^H466Y^ failed to rescue this defect ([Figure 4C,D](#fig4){ref-type="fig"}). In addition, transgenic expression of human wild-type CAMK2A fully rescued this defect, confirming the high degree of functional conservation between CAMK2A homologs, while the patient-derived human CAMK2A^H477Y^ failed to do so ([Figure 4C](#fig4){ref-type="fig"}, bottom panels). These results suggest that the p.H477Y mutation is defective in supporting pre-synaptic function in *C. elegans*.

![CAMK2A^H477Y^ mutant fails to rescue synaptic defects in *unc-43 C. elegans* neurons.\
(**A**) Schematic drawing of *C. elegans* motor neuron, DA9 in the tail region. DA9 extends a dendrite (red) anteriorly and an axon (blue) that extends posteriorly crosses the midline of the animal and anteriorly in the dorsal nerve cord (DNC). It forms approximately 20 *en passant* synapses within a discrete stretch along the DNC (blue box). DA9 presynaptic vesicles were marked with RAB-3 (GFP::RAB-3). The asynaptic region (yellow box) is devoid of any synaptic vesicle accumulation. (**B**) The localization of mCherry::UNC-43 and mCherry::UNC-43(H466Y) in DA9 synapses. Note that UNC-43 accumulates at synaptic boutons while UNC-43(H466Y) is diffusely localized. Fluorescent intensity of mCherry::UNC-43 was measured at synaptic boutons and along the axonal shaft. Graph plots the ratio of fluorescence intensity at synaptic boutons compared to the axonal shaft of 30 synapses from three animals. Graph shows the mean and error bars show SEM, \*\*\*p-value 6.32e^−19^, Student's T-test. (**C**) Representative confocal images demonstrating presynaptic puncta size changes between WT and *unc-43(e408)* mutants. *unc-43* mutants have smaller presynaptic puncta along the DNC. This defect is rescued by expression of either UNC-43 or CAMK2A in DA9 whilst the mutated UNC-43^H466Y^ and CAMK2A^H477Y^ fail to rescue. (**D**) Quantification of average puncta intensity from WT and *unc-43(e408)* animals. Error bars represent SEM with number of synaptic puncta quantified n \> 80, N.S. is not significant, \*\*\*p-value\<0.001 (uninjected vs *unc-43* p-value 5.0e^8^, uninjected vs *unc-43^H466Y^* p-value 4.17, uninjected vs CAMK2A p-value 4.25e^−12^, uninjected vs *CAMK2A^H477Y^* p-value 9.40), One-Way ANOVA with Bonferroni posthoc test. (**E**) Representative confocal images showing mislocalization of GFP::RAB-3 into the asynaptic region (yellow box) in *unc-43* DA9 neuron. (**F**) Rescue of the *unc-43(e408)* phenotype by DA9 cell-specific expression of UNC-43 or CAMK2A. UNC-43^H466Y^ and CAMK2A^H477Y^ fail to rescue the *unc-43* phenotype. Graph shows the percentage of animals with the WT and *unc-43* mutant phenotypes. \*\*\*p\<0.001 (*unc-43* vs *unc-43^H466Y^* p-value 2.13e^−51^, CAMK2A vs CAMK2A^H477Y^ p-value 3.77e^−50^), Fisher Exact test with n = 100 animals scored for each line. (**G**) Behavioral rescue by expressing wild-type UNC-43 or UNC-43^H466Y^ in *unc-43(e408)* mutants. The behavior was scored as either wild-type or unc-43. Two independent worm lines were analyzed for each condition. \*\*\* p-value 5.29e^−41^, Fisher Exact test with n = 100 animals scored for each line.](elife-32451-fig4){#fig4}

Immediately posterior to the stretch of presynaptic puncta is an asynaptic domain within the DA9 axon that is devoid of any RAB-3::GFP fluorescence in wild-type animals ([Figure 4E](#fig4){ref-type="fig"}, top panel). Loss of *unc-43* results in the mislocalization of the synaptic marker RAB3::GFP into this asynaptic region ([Figure 4E](#fig4){ref-type="fig"}, bottom panel). This defect could also be rescued by cell autonomous expression of either *unc-43* or human *CAMK2A*. Patient derived mutation CAMK2A^H477Y^ or the worm homologous mutation UNC-43^H466Y^ both failed to rescue this phenotype ([Figure 4E](#fig4){ref-type="fig"}). In addition, expression of UNC-43^H466Y^ in wild-type animals did not cause any synaptic defect or mislocalizaton of RAB3::GFP, suggesting that the mutation does not have dominant negative effects ([Figure 4F](#fig4){ref-type="fig"}).

We further tested if the patient derived mutation in CAMK2A impacted worm locomotor behavior. Null mutants for *unc-43* are flaccid in posture and move with a flattened uncoordinated waveform. The animals are variably convulsive, often spontaneously contracting and relaxing their body-wall muscles in brief repeating bursts that resemble seizures ([@bib25]). We expressed either wild-type UNC-43 or UNC-43^H466Y^ in the muscles and neurons of *unc-43(e408)* mutant worms and scored the behavior of young adults in a double-blind experiment. Only the wildtype UNC-43 was able to rescue the movement defects in *unc-43(e408)* animals, but not UNC-43^H466Y^, suggesting that UNC-43^H466Y^ is not functional ([Figure 4G](#fig4){ref-type="fig"}). Together, the data show that CAMK2A^H477Y^ is a loss-of-function mutation which fails to support synaptic function in vivo.

In summary, we have identified an autosomal recessive neurodevelopmental syndrome characterized by growth delay, frequent seizures and severe intellectual disability that is caused by a biallelic germline loss-of-function mutation in CAMK2A. Mechanistically this mutation disrupts CAMK2A self-oligomerization and holoenzyme assembly via its association domain. Our functional results are consistent with the high degree of evolutionary conservation of the affected residue H477 in CAMK2A orthologs, as well as previous structural data demonstrating that His477 is located in the interface between two stacked CAMK2A subunits, which together form the basic repeat unit of the ring-shaped holoenzyme ([@bib3]; [@bib34]). The pathogenicity of the biallelic p.H477Y mutation is furthered highlighted by rescue experiments in *C. elegans*, where in contrast to wild-type human CAMK2A the p.H477Y mutant failed to rescue the neuronal and behavioral defect in *unc-43* (CAMK2 ortholog) null worms. Together, these data demonstrate that the loss of function of CAMK2A is the most plausible genetic cause for the neurodevelopmental defects observed in the two affected siblings.

Discussion {#s3}
==========

CAMK2 plays important and evolutionary conserved roles in synaptic plasticity, neuronal transmission and cognition in near all model organisms examined, and several groups have shown that somatic mutations in human CAMK2 isoforms may contribute to neurological disorders ([@bib7]; [@bib27]; [@bib36]). Notably, a de novo p.E183V mutation in the CAMK2A catalytic domain was shown to cause autism spectrum disorder ([@bib33]). This mutation was shown to act in a dominant-negative manner to reduce wild-type CAMK2A auto-phosphorylation and localization to dendritic spines. While this manuscript was under revision, S. Küry *et al*. reported multiple families with intellectual disability caused by de novo, heterozygous mutations in both CAMK2A and CAMK2B kinase and auto-regulatory domains, which disrupted CAMK2 phosphorylation and caused neuronal migratory defects in murine models ([@bib14]).

Our discovery of a novel neuro-developmental syndrome caused by biallelic CAMK2A mutations further broadens the spectrum of human neurological disorders caused by the CAMK2 family of kinases. To the best of our knowledge, this represents the first Mendelian human disease caused by biallelic CAMK2A mutations. Our functional characterization of the novel mutation p.H477Y *in vitro* and *in vivo* also reveal novel insights on how the CAMK2A holoenzyme regulates neuronal function. In contrast to all previously reported mutations in CAMK2A in intellectual disability syndromes, the p.H477Y is located within the C-terminal association domain and results in a partial but significant disruption of self-oligomerization, suggesting that the assembly of CAMK2A oligomers, in addition to its kinase function is required for neuronal function. Interestingly, the CAMK2A^H477Y^ mutant retains the ability to interact with wild-type CAMK2A but not with itself ([Figure 3D](#fig3){ref-type="fig"}). CAMK2A displays very specific cellular and subcellular expression patterns that is important for regulating substrate phosphorylation in cells ([@bib16]; [@bib37]). The p.H477Y missense affects the subcellular localization in neurons and this may affect its ability to function efficiently. These biochemical results provide a mechanistic basis for the autosomal recessive nature of the disease in our family: the p.H477Y allele is hypomorphic and becomes pathogenic when recessively inherited in the homozygous state. We speculate that heterozygous carriers retain sufficient CAMK2A activity for proper neuronal function. As compared to the milder disease phenotypes reported by Kury et. al., the symptoms afflicting the p.H477Y patients likely represent the most severe manifestation of the CAMK2A dysfunction in humans.

Due to the high degree of conservation of CAMK2A across evolution, we employed the established *C. elegans unc-43* mutant to prove the pathogenicity of the p.H477Y mutation. UNC-43 is the worm homologue of vertebrate CAMK2. We demonstrated wild-type human CAMK2A could rescue the locomotive defects of the *unc-43* mutants, while the p.H477Y mutant failed to do so, likely due to its inability to localize into neuronal synapses ([Figure 4](#fig4){ref-type="fig"}). We anticipate this *in vivo* functional assay in *C. elegans* to be widely applicable to assess the pathogenicity of newly discovered CAMK2 alleles found in human diseases.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\                    Designation                                                           Source or reference                                   Identifiers                                                                   Additional information
  or resource                                                                                                                                                                                                                                          
  ------------------------------------------ --------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------
  Gene (human)                               CAMK2A Calcium/Calmodulin Dependent Protein Kinase II Alpha           Uniprot: Isoform B (identifier: Q9UQM7-2)             Q9UQM7-2                                                                      

  Gene (*C. elegans*)                        unc-43 Calcium/Calmodulin-Dependent Protein Kinase type II            Protein UNC-43 isoform d (Wormbase CDS K11E8.1d)      K11E8.1d                                                                      

  Strain, strain background (*C. elegans*)   Worm (C. elegans) N2 Bristol Strain;unc-43(e408)                      Caenorhabditis Genetics Center (CGC) PMID: 17941711   17941711                                                                      

  Recombinant DNA                            pCDH-CMV-MCS-EF1α-Neo                                                 Systems Biosciences (SBI)                             CD514B-1                                                                      

  Recombinant DNA                            pSM vector (a derivative of pPD49.26 with additional cloning sites)   Modified for this paper                               NA                                                                            ADDGENE <https://media.addgene.org/cms/files/Vec95.pdf>

  Recombinant DNA                            pCDH-CMV-CAMK2A-T2A-mCherry                                           This paper; based on pCDH-CMV-MCS-EF1α-Neo            NA                                                                            

  Recombinant DNA                            pMIG-hOCT4                                                            Addgene                                               Plasmid \#17225                                                               

  Recombinant DNA                            MSCV h c-MYC IRES GFP                                                 Addgene                                               Plasmid \#18119                                                               

  Recombinant DNA                            pMIG-hKLF4                                                            Addgene                                               Plasmid \#17227                                                               

  Recombinant DNA                            pMIG-hSOX2                                                            Addgene                                               Plasmid \#17226                                                               

  Cell line (human)                          Patient derived iPS neurons                                           This paper                                            NA                                                                            

  Cell line (human)                          293T                                                                  Lab stock                                             NA                                                                            

  Chemical compound, drug                    MG132                                                                 Sigma-Aldrich                                         M7449                                                                         

  Commercial kit                             NativeMark PAGE                                                       ThermoFisher                                          BN1002BOX                                                                     

  Commercial kit                             TnT Quick Coupled Transcription/Translation System                    Promega                                               L1170                                                                         

  Antibody                                   Anti-FLAG Clone M2                                                    Sigma-Aldrich                                         F3165                                                                         

  Antibody                                   Anti-HA Clone Y-11                                                    Santa Cruz Biotechnology                              sc-7392                                                                       

  Antibody                                   Anti-GADPH                                                            Santa Cruz Biotechnology                              sc-47724                                                                      

  Antibody                                   Anti-Tuj1                                                             Covance Research                                      MMS-435P                                                                      

  Antibody                                   Anti-MAP2                                                             Synaptic Systems                                      188 004                                                                       

  Cell culture reagent                       20% Knock Out Serum Replacement                                       Thermo Fisher                                         10828--028                                                                    

  Cell culture reagent                       bFGF                                                                  Stemgent                                              37316                                                                         

  Cell culture reagent                       Matrigel Basement Membrane Matrix                                     Corning                                               354234                                                                        

  Cell culture reagent                       mTeSR1                                                                STEMCELL Technologies                                 85850                                                                         

  Cell culture reagent                       CytoTune-iPS 2.0 Sendai Reprogramming Kit                             ThermoFisher                                          A16517                                                                        

  Cell line (human)                          H1 embryonic stem cells                                               Gift from Dr. Lawrence W. Stanton, WiCell             RRID:[CVCL_C813](https://scicrunch.org/resolver/CVCL_C813)                    

  Antibody                                   Alexa Fluor 594 secondary Ab                                          ThermoFisher                                          Cat\# A-11076, RRID:[AB_2534120](https://scicrunch.org/resolver/AB_2534120)   

  Antibody                                   Alexa Fluor 488 secondary Ab                                          ThermoFisher                                          Cat\# A-11001, RRID:[AB_2534069](https://scicrunch.org/resolver/AB_2534069)   

  Assay system/kit                           Maestro MEA System                                                    Axion Biosystem                                       \-                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Disease diagnosis and informed consent {#s4-1}
--------------------------------------

Patients were identified and diagnosed by clinical geneticists at King Hussein Medical Centre, Amman, Jordan. Informed consent was obtained from the families for genetic testing in accordance with approved institutional ethical guidelines (Institute of Medical Biology, Singapore, A\*STAR, Singapore, NUS-IRB reference code 10--051). For patients in [Figure 1](#fig1){ref-type="fig"}, informed consent to publish photographs and videos was obtained from parents. Genomic DNA samples were isolated from saliva using the Oragene DNA collection kit (OG-500, DNAGenotek) and a punch skin biopsy was taken from patient II.4.

Whole exome sequencing {#s4-2}
----------------------

Whole exome sequencing of proband II-1 was performed using the Illumina TruSeq Exome Enrichment Kit for exome capture using 1 ug of genomic DNA. Illumina HiSeq2000 High-output mode was used for sequencing as 100 bp paired-end runs at the UCLA Clinical Genomics Centre and at the UCLA Broad Stem Cell Research Centre as previously described ([@bib9]). An average coverage of 34X was achieved across the exome with 87% of these bases covered at ≥10X. After filtering, a total of 73 homozygous, 125 compound heterozygous and 493 heterozygous variants were protein-changing variants with population minor allele frequencies \< 1%.

Homozygosity mapping {#s4-3}
--------------------

Both parents and their five children were genotyped using Illumina Humancore-12v1 BeadChips following manufacturer's instructions. Call rates were above 99%. Gender and relationships were verified using Illumina BeadStudio. Mapping was performed by searching for shared regions that are homozygous and identical-by-descent (IBD) in the two affected children using custom programs written in the Mathematica (Wofram Research, Inc.) data analysis software (Source code file 1 - IBD linkage program). Candidate regions were further refined by exclusion of common homozygous segments with any unaffected family members. The confidence criteria to identify IBD blocks were a minimum of 5 cM. We identified one shared candidate loci on chromosome 5.

Cell culture and plasmid transfection {#s4-4}
-------------------------------------

HEK 293 T cells (ATCC Cat\# CRL-3216, RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063), from Lab Stock) were cultured in DMEM media (Gibco) supplemented with 10% FBS. Cell line identity was authenticated by commercial human STR profiling with ATCC (ATCC, \#135-XV). All cell lines used in this paper tested negative for mycoplasma using Lonza MycoAlert (Lonza LT07). For transient transfection, 6 × 10^5^ cells per well were seeded in 6 well plates 24 hr before being transfected with Lipofectamine 2000 (ThermoFisher)-complexed plasmids in OPTIMEM (ThermoFisher). To construct the CAMK2A expression plasmids, human CAMK2A cDNA was PCR-amplified from ImageClone with AscI and PacI restriction sites and cloned into pCDNA3.1 with an N-terminal 3xFLAG or 3xHA tag. All CAMK2A mutants were generated using QuikChange XL (Agilent). Cells were treated with MG132 (Sigma, M8699) at 5 µM to block proteasome degradation.

Generation of iPSCs {#s4-5}
-------------------

### Control iPSCs from an unrelated but ethnically and sex-matched individual {#s4-5-1}

Fibroblasts were transduced with *OCT4*, *SOX2*, *KLF4* and *c-MYC* (Addgene plasmids \#17225, \#17226, \#17227 were gifts from George Daley, and \#18119 a gift from John Cleveland) as previously described ([@bib23]). After 4 days, transduced cells were reseeded onto irradiated mouse embryonic fibroblast in human ES cell medium (DMEM/F12 (Sigma, D6421) supplemented with 20% Knock Out Serum Replacement (Thermo Fisher Scientific, 10828--028), 0.1 mM 2-mercaptoethanol (Thermo Fisher Scientific, 21985--023), 2 mM L-glutamine (Thermo Fisher Scientific, 25030), 0.2 mM NEAA (Thermo Fisher Scientific, 11140--050) and 5 ng/mL bFGF (Stemgent, 03--0002). iPSC colonies were picked between days 17--28 and maintained in matrigel (Corning, 354234) and mTeSR1 (STEMCELL Technologies, 85850) for expansion.

### Patient-derived iPSC from proband, II.4 {#s4-5-2}

Dermal primary fibroblasts were reprogrammed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, A16517) in accordance with the manufacturer's instructions. Cells were passaged and plated onto irradiated mouse embryonic feeders 7 days after viral transfection in human ES cell medium (DMEM/F12 (Sigma, D6421) supplemented with 20% Knock Out Serum Replacement (Thermo Fisher Scientific, 10828--028), 0.1 mM 2-mercaptoethanol (Thermo Fisher Scientific, 21985--023), 2 mM L-glutamine (Thermo Fisher Scientific, 25030), 0.2 mM NEAA (Thermo Fisher Scientific, 11140--050) and 5 ng/mL bFGF (Stemgent, 03--0002). iPSC colonies were picked between days 17--28 and maintained in Matrigel Basement Membrane Matrix (Corning, 354234) and mTeSR1 (STEMCELL Technologies, 85850) for expansion.

Neuronal differentiation and Multi-electrode Array Recordings {#s4-6}
-------------------------------------------------------------

iPSCs-derived NPCs were differentiated into neurons for 21 days using a previously published protocol ([@bib39]). Briefly, NPCs were plated at a density of 50,000 cells/cm^2^ in a poly-L-ornithine and laminin-coated plates, cultured in N2B27 medium supplemented BDNF (20 ng/ml), GDNF (20 ng/ml), cAMP (N6,2'-O-dibutyryladenosine 3',5'-cyclic monophosphate; Sigma; 0.3 mM) and ascorbic acid (0.2 mM). H1 embryonic stem cells (Gift from Lawrence W. Stanton, WiCell, RRID:[CVCL_C813](https://scicrunch.org/resolver/CVCL_C813)) were also differentiated into neurons to use as controls. H1 embryonic stem cells were verified by karyotyping (Cytogenetics Laboratory, KK Women\'s and Children\'s Hospital, Singapore) and checked for pluripotency by differentiation into the three germ layers marked by Nestin (ectoderm), AFP (endoderm) and ASM-1 (mesoderm). For the immunofluorescence staining, neurons were fixed for 15 min in ice cold 4% (w/v) paraformaldehyde. Permeabilization using 0.3% (v/v) Triton-X in 1X PBS was performed for 10 min then incubated with 1:1000 mouse anti-Tuj1 (Covance Research Products Inc Cat\# MMS-435P, RRID:[AB_2313773](https://scicrunch.org/resolver/AB_2313773)), 1:1500 guinea pig anti-MAP2 (Synaptic Systems Cat\# 188 004, RRID:[AB_2138181](https://scicrunch.org/resolver/AB_2138181)) overnight at 4°C in 5% (w/v) BSA diluted with 1X PBS. For visualization, 1:1000 secondary antibody conjugated to Alexa Fluor 594 (Thermo Fisher Scientific Cat\# A-11076, RRID:[AB_2534120](https://scicrunch.org/resolver/AB_2534120)) or Alexa Fluor 488 (Thermo Fisher Scientific Cat\# A-11001, RRID:[AB_2534069](https://scicrunch.org/resolver/AB_2534069)) was applied. Counter staining for nuclei were performed using Dapi. Images were captured using the FV3000 Olympus confocal.

For the multi-electrode array (MEA) recordings, neurons on day 21 were dissociated and replated on 0.1 polyethylenimine (Sigma)-coated 48 well MEA plates (Axion Biosystems) in BrainPhys media supplemented with BDNF, GDNF, cAMP and ascorbic acid as previously described ([@bib40]). Spontaneous neuronal activity was observed and recorded at 37°C for 5 min every 2--3 days using the Maestro MEA System (Axion Biosystem). Independent measurements were taken from seven wells for each condition (technical replicates).

*In vitro* transcription/translation and co-immunoprecipitation {#s4-7}
---------------------------------------------------------------

CAMK2A proteins were synthesized *in vitro* using TNT T7 Quick Coupled Transcription/Translation (Promega) with 1 μg of plasmids in 20 μl reaction volumes for 90 mins at 30°C. For co-immunoprecipitation, the reactions were diluted 10x in TBS (100 mM Tris-HCl, pH = 8, 150 mM NaCl) with 1% Nonidet P40 (NP40) and incubated with 10 μl anti-FLAG M2 agarose beads (Sigma) at 4°C overnight. Proteins were eluted with 1x Laemmli buffer after 3 washes in the 1xTBS with 1% NP40.

Protein electrophoresis and immunoblotting {#s4-8}
------------------------------------------

Total protein lysate was quantified using a standard Bradford assay and 10 μg of lysate was used for immunoblotting experiments. For Blue Native PAGE, cells were lysed in 1x Sample Preparation buffer (ThermoFisher) containing 1% digitonin. 1% SDS was supplemented for SDS-PAGE. All proteins were transferred to PVDF membranes using TurboBlot (Bio-rad) at 2.5 mA for seven mins. The primary antibodies used were anti-FLAG (M2, Sigma-Aldrich Cat\# F3165, RRID:[AB_259529](https://scicrunch.org/resolver/AB_259529)), anti-GAPDH (Santa Cruz Biotechnology Cat\# sc-47724, RRID:[AB_627678](https://scicrunch.org/resolver/AB_627678)) and anti-HA (Y-11, Santa Cruz Biotechnology Cat\# sc-805, RRID:[AB_631618](https://scicrunch.org/resolver/AB_631618)). The secondary antibodies were anti-rabbit IgG-HRP (Jackson ImmunoResearch Labs Cat\# 111-035-003, RRID:[AB_2313567](https://scicrunch.org/resolver/AB_2313567)), anti-mouse IgG-HRP (light chain specific) (Jackson ImmunoResearch Labs Cat\# 205-032-176, RRID:[AB_2339056](https://scicrunch.org/resolver/AB_2339056)) and anti-mouse IgG-HRP (Jackson ImmunoResearch Labs Cat\# 115-035-003, RRID:[AB_10015289](https://scicrunch.org/resolver/AB_10015289)).

Worm strains {#s4-9}
------------

All strains were maintained at 20°C on OP50 *E. coli* nematode growth medium plates as described ([@bib4]). N2 Bristol strain worms (WB Cat\# CB4852, RRID:[WB-STRAIN:CB4852](https://scicrunch.org/resolver/WB-STRAIN:CB4852)) were used as the WT reference, and the *unc-43(e408)* mutant was used. To visualize synaptic vesicles in DA9 neuron, *wyIs85* \[Pitr-1::GPF::RAB-3\] was used ([@bib13]).

Transgenic lines {#s4-10}
----------------

OTL70 *wyIs85*\[Podr-1::dsred, Pitr-1::gfp::rab-3\]; *jpnEx40*\[Podr-1::gfp, Pmig-13::unc-43\]

OTL71 wyIs85; *jpnEx41*\[Podr-1::gfp, Pmig-13::unc-43\]

OTL72 *unc-43(e408); wyIs85; jpnEx44*\[Podr-1::gfp, Pmig-13::unc-43(H466Y)\]

OTL73 *unc-43(e408); wyIs85; jpnEx45*\[Podr-1::gfp, Pmig-13::unc-43(H466Y)\]

OTL74 *unc-43(e408); wyIs85; jp*nEx42\[Podr-1::gfp, Pmig-13::unc-43\]

OTL75 *unc-43(e408); wyIs85; jpnEx43*\[Podr-1::gfp, Pmig-13::unc-43\]

OTL76 *unc-43(e408); wyIs85; jpnE*x47\[Podr-1::gfp, Pmig-13::*CAMK2A*\]

OTL77 *unc-43(e408); wyIs85; jpnEx*48\[Podr-1::gfp, Pmig-13::*CAMK2A*\]

OTL78 *unc-43(e408); wyIs85; jpnEx49*\[Podr-1::gfp, Pmig-13::*CAMK2A*^H477Y^\]

OTL79 *unc-43(e408); wyIs85; jpnEx50*\[Podr-1::gfp, *Pmig-13::CAMK2A*^H477Y^\]\]

OTL82: jpnEx54\[Podr-1::gfp, Pmig-13::mcheery::unc-43\]

OTL83: jpnEx55\[Podr-1::gfp, Pmig-13::mcherry::unc-43\]

OTL84: jpnEx56\[Podr-1::gfp, Pmig-13::mcherry::unc-43(H466Y)\]

OTL85: jpnEx57\[Podr-1::gfp, Pmig-13::mcherry::unc-43(H466Y)\]

OTL86: unc-43(e408); jpnEx58\[Punc-122::dsred, Punc-104::mcherry::unc-43, Phlh-1::mcherry::unc-43\]

OTL87: unc-43(e408); jpnEx59\[Punc-122::dsred, Punc-104::mcherry::unc-43, Phlh-1::mcherry::unc-43\]

OTL88: unc-43(e408); jpnEx60\[Punc-122::dsred, Punc-104::mcherry::unc-43(H466Y), Phlh-1::mcherry::unc-43(H466Y)\]

OTL89: unc-43(e408); jpnEx61\[Punc-122::dsred, Punc-104::mcherry::unc-43(H466Y), Phlh-1::mcherry::unc-43(H466Y)\]

Plasmids for transgenic expression in worms {#s4-11}
-------------------------------------------

Expression plasmids for transgenic worm lines were made using the pSM vector (C. Bargmann), a derivative of pPD49.26 (A. Fire). The *mig-13* promoter was cloned between SphI/AscI, and C.elegans *unc-43* isoform d or human *CAMK2α* was cloned between NheI/KpnI or AscI/NheI, respectively. P.H466Y and p.H477Y mutations were introduced by PCR-based mutagenesis using KOD-plus- high fidelity DNA polymerase (TOYOBO, Tokyo, Japan). Transgenic worms were generated as described ([@bib21]). Plasmids were injected into animals at 10 ng/μl (in the case of Pmig-13::unc-43) and 50 ng/μl (in the case of Pmig-13::*CAMK2α*) together with coinjection markers at 90 ng/μl.

Fluorescence quantification and confocal imaging {#s4-12}
------------------------------------------------

All fluorescence images of DA9 were taken in live worms immobilized with 5% agar pad, 10 μM levamisol (Sigma) and 0.1 mm polystylene beads (Polysciences, Inc., Warrington, PA, USA) with a 63×/1.4 NA objective on a Zeiss Axioplan 2 Imaging System or a Plan-Apochromat 63×/1.3 objective on a Zeiss LSM710 confocal microscope using similar imaging parameters for the same marker across different genotypes. Fluorescence quantification was determined using Image J software (ImageJ, RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)).

Behavioral analysis {#s4-13}
-------------------

*mcherry::unc-43* or *mcherry::unc-43(H466Y)* were expressed in *unc-43*(*e403*) mutant worms using both *unc-104* promoter (neuron-specific promoter) and *hlh-1* promoter (muscle-specific promoter). Two independent lines were established and analyzed. The behavioral phenotype of the transgenic worms was scored in a double-blind manner using a stereo microscope (SZX16, Olumpus, Tokyo, Japan). From the movement behavior on OP50 feeder NGM plates, each worm was classified to behave like '*wild-type*' or '*unc-43*'. 100 worms were observed for each genotype on the same day from two independently derived transgenic lines.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A homozygous loss-of-function *CAMK2A* mutation causes growth delay, frequent seizures and severe intellectual disability\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and K VijayRaghavan as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Karl Giese (Reviewer \#1); A.J Robison (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

All reviewers have substantive comments, most of which are non-overlapping. Some of the comments require you to carry out new experiments. For submitting a revised version, it is essential that you address all the comments of all the reviewers. Along with your revised submission, please attach a point-by-point statement of the actions taken by you. If you disagree with any of the points raised by the reviewers, please state so with justification in your actions-taken-report.

Reviewer \#1:

This manuscript is of fundamental importance for the CaMKII field, as for the first time it makes a convincing case that CaMKII dysfunction is relevant for brain diseases. The strength of the manuscript is that a family is described where two children are homozygous for a missense mutation in CaMKIIalpha. Biochemical characterisation of the missense mutation strongly suggests that this mutation causes loss-of function, by not only preventing oligomerisation of CaMKIIalpha subunits, but also mislocalising CaMKIIalpha to the nucleus and enhancing the proteasomal dedragation of the kinase subunits. I think that this work is important that it deserves to be published in *eLife*. I have some suggestions that can further strengthen the manuscript:

1\) I could not find any data regarding impaired intellectual disability. If possible, could such data be included?

2\) Regarding the table in Figure 1---figure supplement 1, it would be amazing if data for heterozygous and wild-type children could be included. This would provide very strong evidence that specifically the missense mutation causes the observed phenotypes. Would you have patient consent to include such information?

3\) The authors found that the identified missense mutation mislocalizes CaMKIIalpha to nucleus in a non-neuronal cell line. If possible, it would be good to show that this also happens in primary neurons. This would suggest that CaMKIIalpha with the missense mutation is not delivered to synapses, substantially blocking synaptic plasticity.

4\) Unfortunately, the presented in vivo studies with *C. elegans* focus on the wrong neuronal cell type. In mammals CaMKIIalpha is expressed exclusively in glutamatergic neurons (not cholinergic motoneurons). Therefore, I think that Figure 2 must be removed from the manuscript, as the findings are misleading. \-- In my opinion, for this manuscript it is not necessary to include in vivo data. However, if authors wish to include in vivo data, then they should focus on the correct neuronal cell type in any in vivo system.

Reviewer \#2:

Chia and colleagues have authored a potentially important manuscript identifying an association between a novel homozygous missense mutation in CAMK2A and global neurodevelopmental delay with severe intellectual disability, seizures, and delayed growth. Although interesting, a number of major issues need to be addressed:

1\) Substantially more details are required regarding the genetic analysis, in order to better establish the likely causality of the candidate CAMK2A mutation. In particular, the workflow by which the proposed causative variant has been identified needs to be much better clarified.

a\) Can the authors provide additional pedigree data regarding the parental consanguineous relationship? If not, then on what basis are the parents reported as consanguineous?

b\) The authors should provide the genome-wide results of the homozygosity mapping prior to filtering out homozygous segments found in the unaffected family members, and prior to filtering for regions of homozygosity \>5cM.

c\) On what basis have the authors established the \"confidence criteria to identify IBD blocks were a minimum of 5 cM\"?

d\) Regarding the variants identified by exome sequencing, the authors should minimally provide a list of all 72 homozygous protein-coding variants with MAF\<1%, and sufficient information to determine their localization within the regions of homozygosity in all of the genotyped family members.

2\) Functional experiments: a) The authors convincingly establish that the H477Y mutation blocks oligomerization of the CAMK2A holoenzyme. However, they subsequently attempt to evaluate protein stability using MG132. I have some difficulties with this experiment.

Specifically, how can it be that in the DMSO treated lysates (Figure 2---figure supplement 2C), such big differences are found between the different CAMK2A construct expression levels, whereas in Figure 1H the expression levels are similar?

Was each experiment done at different time points after transfection?

How do the authors control for transfection efficiency? Based on the results shown here, in the absence of a demonstration that the transfection efficiency was equal across the various constructs, it is difficult to reach a firm conclusion regarding the stability or expression levels of CAMK2A \[H477Y\].

b\) Figure 2C and 2E: The images provided are consistent with a rescue of the synaptic phenotype when expressing either Unc-43 or wild-type human CAMK2, but not with the H477Y mutant. However, the experimental design is unclear.

The legend reports n\>80 (Figure 2C) and n=100 (Figure 2E). But what does \'n\' represent (e.g., is this the number of puncta, images, or worms measured)? For Figure 2C, why is it not possible to provide an exact value?

c\) Figure 2C: Why do the authors use a Student\'s t-test for these data? If they want to compare the different conditions, a one-way ANOVA with post-hoc correction should be applied.

d\) Figure 2D: By what criteria have the authors defined the asynaptic region?

e\) The Unc-43 worm has clear phenotypes, as the authors themselves describe in the Results section: \"Null mutants for unc-43 are flaccid in posture and move with a flattened uncoordinated waveform.\" These phenotypes are very clear. Why didn\'t they try rescuing these phenotypes? This would have provided a much stronger opportunity to assess the functional relevance of the rescue experiments.

f\) What is the relevance of examining the localization of the association domain? The authors reason that since the mutation blocks oligomerization, it is more likely to diffuse through the nuclear pore, thereby reducing cytosolic accumulation. But does the association domain itself oligomerize in HEK293T cells?

The authors seem to infer on the basis of these experiments that CAMK2A is likely to be mislocalized in the homozygous H477Y carriers. However, they would need to show the same experiment using full-length reference and mutant CAMK2A in order to establish more definitive evidence.

Reviewer \#3:

The manuscript \"A homozygous loss-of-function CaAMK2A mutation causes loss of growth, frequent seizures, and severe intellectual disability\" uses sequencing of patient DNA, biochemistry, and *C. elegans* phenotyping to characterize a novel coding mutation preventing holoenzyme formation in CaMKIIalpha protein in humans. The authors demonstrate that an autosomal recessive mutation in a histidine residue critical for association domain interactions is associated with disease state in a human family, then go on to use traditional biochemistry to show that this mutant kinase forms interactions with WT but not with itself, a finding beautifully consistent with the recessive nature of the disease state. Further, they use a rescue strategy in a *C. elegans* model lacking expression of the CaMKII homolog to show that neither the human nor the worm kinase with this mutation can rescue worm phenotype, while either WT kinase does so. Because CaMKII has long been associated with cognition through mostly mouse studies but has never before been directly and causally tied to a human cognitive disorder, this is a very exciting finding that will help to validate and reinvigorate study of this essential molecule. The paper is clear and well-written, the experiments directly address the hypotheses and are appropriately interpreted (for the most part -- see below), and the findings are certain to strongly impact the field. I have some minor concerns below about interpretation and mechanism, and one somewhat larger concern:

The *C. elegans* experiments are very convincing. However, I wonder whether the mutant and WT CaMKII proteins used in the rescue experiments have the same localization. This ought to be very easy to determine by immunofluorescence, even if the constructs aren\'t tagged. Does the mutant accumulate in the nucleus of the *C. elegans* neurons as it does in HEK cells? Does the WT adopt a postsynaptic localization? Data such as these would greatly strengthen the manuscript.

Overall, I am highly enthusiastic about this manuscript.

10.7554/eLife.32451.018

Author response

> Reviewer \#1:
>
> This manuscript is of fundamental importance for the CaMKII field, as for the first time it makes a convincing case that CaMKII dysfunction is relevant for brain diseases. The strength of the manuscript is that a family is described where two children are homozygous for a missense mutation in CaMKIIalpha. Biochemical characerisation of the missense mutation strongly suggests that this mutation causes loss-of function, by not only preventing oligomerisation of CaMKIIalpha subunits, but also mislocalising CaMKIIalpha to the nucleus and enhancing the proteasomal degradation of the kinase subunits. I think that this work is important that it deserves to be published in eLife. I have some suggestions that can further strengthen the manuscript:
>
> 1\) I could not find any data regarding impaired intellectual disability. If possible, could such data be included?

The clinicians cannot obtain a definitive IQ test since both affected siblings are non-verbal and do not respond to verbal cues. We believe that the supplementary videos do convey the extent and severity of the ID in both affected siblings.

> 2\) Regarding the table in Figure 1---figure supplement 1, it would be amazing if data for heterozygous and wild-type children could be included. This would provide very strong evidence that specifically the missense mutation causes the observed phenotypes. Would you have patient consent to include such information?

We have confirmed that the healthy siblings (who are either heterozygous or non-carrier for the CAMK2A ^H477Y^ allele) do not display any signs of neuro-developmental delay. We have updated the clinical table in Figure 1---figure supplement 1 to include all five siblings.

> 3\) The authors found that the identified missense mutation mislocalizes CaMKIIalpha to nucleus in a non-neuronal cell line. If possible, it would be good to show that this also happens in primary neurons. This would suggest that CaMKIIalpha with the missense mutation is not delivered to synapses, substantially blocking synaptic plasticity.

We have significantly revised our initial biochemical analyses of overexpressed CAMK2A mutant. In the initial submission, the nuclear localization was shown using GFP-tagged to the CAMK2A association domain, but not with the full length CAMK2A protein. We did not mean to claim that full length CAMK2A would mislocalize in vivo. Instead, we simply used nuclear exclusion as an in vitro assay to test the oligomerization of CAMK2A association domain.

We have removed these data to avoid any confusion and replaced them with a more rigorous functional experiment using neurons derived from the proband's iPS cells. These new results demonstrate a profound impairment in neuronal activity in patient's neurons that are cultured in vitro (Figure 2) suggesting that endogenous CAMK2A^H477Y^ is most likely dysfunctional.

We have attempted to decipher the localization of endogenous CAMK2A by immunofluorescence in iPSC-derived neurons. However, all five commercial CAMK2A antibodies tested failed to give a single band by Western blot using lysates from wild-type neurons ([Author response image 1](#respfig1){ref-type="fig"}). Likewise, these antibodies could not reflect the synaptic localization of wild-type CAMK2A in iPSC-derived neurons using IF. We therefore could not carry out a rigorous evaluation of the localization of the CAMK2A^H477Y^ in iPSCs-derived neurons.

![](elife-32451-resp-fig1){#respfig1}

> 4\) Unfortunately, the presented in vivo studies with C. elegans focus on the wrong neuronal cell type. In mammals CaMKIIalpha is expressed exclusively in glutamatergic neurons (not cholinergic motoneurons). Therefore, I think that Figure 2 must be removed from the manuscript, as the findings are misleading. \-- In my opinion, for this manuscript it is not necessary to include in vivo data. However, if authors wish to include in vivo data, then they should focus on the correct neuronal cell type in any in vivo system.

We understand your concern that in mammals, CAMK2A is mostly found in glutamatergic neurons. In vertebrates, CAMKII isoforms are encoded by at least four genes (⍺, β, γ, δ). In the worm, the *unc-43* gene encodes only one CaMKII orthologue which is found in all neurons. Mutations in *unc-43* cause multiple behavioral defects in locomotory activity, in the clock control of defecation, in the regulation of body-wall muscle excitation and spontaneous activity (David et al., 1999). Thus in *C. elegans, unc-43* can perform all these functions regardless of the neuronal cell type in which it is expressed.

CAMK2 is highly conserved from humans to worm. We show in Figure 4C and 4F that the human CAMK2A orthologue is able to fully rescue synaptic defects due to the loss of *unc-43* in the DA9 neuron. This indicates that the human CAMK2A functions similarly in cholinergic neurons of *C. elegans*. More importantly, the identified patient mutation p.H477Y when introduced in either UNC-43 or CAMK2A, is unable to rescue the *unc-43* synaptic defects.

To further strengthen this data, we have performed behavioural rescue experiments by expressing either wildtype or H466Y mutated UNC-43 protein in worms defective for *unc-43.* We have used a pan-neuronal promoter to express UNC-43 in all neurons and scored the phenotype in a double-blind experimental setup. Consistently, we observe that the wildtype UNC-43, but not UNC-43^H466Y^, is able to fully rescue all behavioral defects of *unc-43* worms. This is providing further evidence that the patient identified mutation renders CAMK2A non-functional in multiple in vivo assays.

We believe the *C. elegans* data are key to prove the pathogenicity of this human allele. They are now complemented by functional assays using patient IPSCs-derived neurons (Figure 2).

> Reviewer \#2:
>
> Chia and colleagues have authored a potentially important manuscript identifying an association between a novel homozygous missense mutation in CAMK2A and global neurodevelopmental delay with severe intellectual disability, seizures, and delayed growth. Although interesting, a number of major issues need to be addressed:
>
> 1\) Substantially more details are required regarding the genetic analysis, in order to better establish the likely causality of the candidate CAMK2A mutation. In particular, the workflow by which the proposed causative variant has been identified needs to be much better clarified.

We have included in this revised manuscript, a more detailed description of the pipeline, including IBD mapping, whole-exome sequencing and data filtering. We are adhering to our standard operating procedures which have allowed us to genetically diagnose numerous Mendelian disorders over the years (Reversade et al., 2009; Bonnard et al., 2012; Hu and Pomp, 2014; Cetinkaya and Xiong, 2016; Zhong et al., 2016; Gordon and Xue, 2017).

> a\) Can the authors provide additional pedigree data regarding the parental consanguineous relationship? If not, then on what basis are the parents reported as consanguineous?

We could not obtain additional medical record from members of the extended family. We confirm that parents are first cousins as stated by them during several clinical visits. This is independently verified from the SNP genotyping analysis of their 5 children. On average, 10% of the children's genomes are homozygous- proving that their parents are at least first cousins.

\% of homozygosity in all children from familyChildMb% homozygousII-1309.410.3II-2319.210.6II-3378.212.6II-4310.210.3II-5183.16.1

> b\) The authors should provide the genome-wide results of the homozygosity mapping prior to filtering out homozygous segments found in the unaffected family members, and prior to filtering for regions of homozygosity \>5cM.

These data are now provided in Supplemental file 1 and Figure 1---figure supplement 1D.

> c\) On what basis have the authors established the \"confidence criteria to identify IBD blocks were a minimum of 5 cM\"?

IBD regions \<5 cM are likely to be false positives. According to Duran et al., (2014), \"most 2--3 cM segments are erroneous and only segments longer than 5 cM have a negligible number of false positives\".

> d\) Regarding the variants identified by exome sequencing, the authors should minimally provide a list of all 72 homozygous protein-coding variants with MAF\<1%, and sufficient information to determine their localization within the regions of homozygosity in all of the genotyped family members.

These data are now provided in Figure 1---figure supplement 1E, with a thorough description in the text. Briefly, four homozygous variants from the proband's exome were identified within the chromosome 5 IBD candidate block. Notably, homozygotes for these variants, except the CAMK2A^H477Y^ allele, have been identified in public sequencing databases, such as ExAC and GnomAD, and therefore can be ruled out.

> 2\) Functional experiments: a) The authors convincingly establish that the H477Y mutation blocks oligomerization of the CAMK2A holoenzyme. However, they subsequently attempt to evaluate protein stability using MG132. I have some difficulties with this experiment.
>
> Specifically, how can it be that in the DMSO treated lysates (Figure S2C), such big differences are found between the different CAMK2A construct expression levels, whereas in Figure 1H the expression levels are similar?
>
> Was each experiment done at different time points after transfection?
>
> How do the authors control for transfection efficiency? Based on the results shown here, in the absence of a demonstration that the transfection efficiency was equal across the various constructs, it is difficult to reach a firm conclusion regarding the stability or expression levels of CAMK2A \[H477Y\].

Thank you for encouraging us to improve these results. These experiments have been significantly revised with improved constructs consisting of a single cistronic T2A-mCherry cassette to control for both transfection and translation efficiency. These results are described in Figure 3E, 3F and Figure 2---figure supplement 2B.

> b\) Figure 2C and 2E: The images provided are consistent with a rescue of the synaptic phenotype when expressing either Unc-43 or wild-type human CAMK2, but not with the H477Y mutant. However, the experimental design is unclear.
>
> The legend reports n\>80 (Figure 2C) and n=100 (Figure 2E). But what does \'n\' represent (e.g., is this the number of puncta, images, or worms measured)? For Figure 2C, why is it not possible to provide an exact value?

We have made changes in the legend text to clarify the exact parameter of measurement for each experiment. For instance, "error bars represent SEM with number of synaptic puncta quantified n\> 80" and "Graph shows the percentage of animals with the WT and *unc-43* mutant phenotypes with n=100 animals scored for each line".

> c\) Figure 2C: Why do the authors use a Student\'s t-test for these data? If they want to compare the different conditions, a one-way ANOVA with post-hoc correction should be applied.

The statistics for experiments comparing multiple conditions has been revised according to your suggestions. We have implemented a one-way ANOVA test with either Bonferroni post-hoc test or two-way ANOVA with Tukey post-hoc test.

> d\) Figure 2D: By what criteria have the authors defined the asynaptic region?

The asynaptic region is the defined as the part of the axon extending out from the DA9 cell body to the first *en passant* synapse located on the dorsal part of the axon. It has been shown that the positional information required to define this asynaptic region is controlled by *lin-44*/Wnt secreted by four hypodermal cells in the tail of the worm (Klassen and Shen, (2007). This asynaptic region of the axon is also defined by different synaptic vesicle transport dynamics as compared to the dendrite and distal axon of DA9 (Maeder et al., (2014).

> e\) The Unc-43 worm has clear phenotypes, as the authors themselves describe in the Results section: \"Null mutants for unc-43 are flaccid in posture and move with a flattened uncoordinated waveform.\" These phenotypes are very clear. Why didn\'t they try rescuing these phenotypes? This would have provided a much stronger opportunity to assess the functional relevance of the rescue experiments.

We have carried out a behavioral rescue as shown Figure 3G: in contrast to UNC-43^wild-type^, UNC-43^H466Y^ which is homologous to CAMK2A^H477Y^, completely failed to rescue the uncoordinated and convulsive phenotype of the mutant *unc-43* worms. Thank you for suggesting this crucial experiment which provides further support to our initial observation.

> f\) What is the relevance of examining the localization of the association domain? The authors reason that since the mutation blocks oligomerization, it is more likely to diffuse through the nuclear pore, thereby reducing cytosolic accumulation. But does the association domain itself oligomerize in HEK293T cells?

We have removed these data to avoid any confusion. Our biochemical data using native PAGE and co-immunoprecipitation (Figure 3C,D) support the oligomerization defect when CAMK2A was expressed in 293T cells as well as when translated in vitro.

> The authors seem to infer on the basis of these experiments that CAMK2A is likely to be mislocalized in the homozygous H477Y carriers. However, they would need to show the same experiment using full-length reference and mutant CAMK2A in order to establish more definitive evidence.

These experiments are now shown in Figure 3E and Figure 2---figure supplement 2B, with full length CAMK2A. We focused on the most striking difference, which was the reduction in overall level in mutant CAMK2A.

[^1]: ^\*^These authors contributed equally.

[^2]: These authors contributed equally to this work.
